AKR1A1

Across TCGA pan-cancer cohorts, AKR1A1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AKR1A1 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AKR1A1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AKR1A1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where AKR1A1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.516	0.302	<.001	76	view →
HNSC	DFS	Median	III,IV	0.866	0.695	.022	14	view →
CCRCC	OS	Tertile	III,IV	0.753	0.456	.019	7	view →
OV	DFS	Median	All	0.702	1.000	.035	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AKR1A1–PDAC (DFS)

Open the PDAC breakdown →